Cyclacel Q4 net loss $7.4M, cash $18.3M; fadraciclib Phase 2 on track for 1H 2023

Bio Green Med Solution, Inc.

Net loss Q4 2022 $7.4M, full year $21.2M; cash $18.3M as of Dec 31, 2022.
R&D expenses $6.7M (Q4) and $20.3M (FY) driven by fadraciclib and plogosertib trials.
Cash runway estimated into Q4 2023 including $4.7M UK R&D tax credit receivable.
On track to start oral fadraciclib Phase 2 proof-of-concept in 1H 2023; interim data expected 2H 2023.
Expect final data from fadraciclib dose escalation and initial data from plogosertib dose escalation in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bio Green Med Solution, Inc. reported the year ended December 31, 2022 results: net income $21.2 million.

Period: the year ended December 31, 2022
Net income: $21.2 million
Result: reported results

Exact text from the filing

Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bio Green Med Solution, Inc. reported the three months ended December 31, 2022 results: net income $7.4 million.

Period: the three months ended December 31, 2022
Net income: $7.4 million
Result: reported results

Exact text from the filing

Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-029007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.